Selection of dose in BE study of Ivermectin 3 mg tabs for EU [Design Issues]

posted by Deep patel – India, 2016-06-03 15:34 (2855 d 02:25 ago) – Posting: # 16390
Views: 5,127

Dear All,

As per FDA's Bioequivalence recommendations for Ivermectin 3mg tablets, they recommended to conduct single dose, two-way crossover fasting study with 2 x 3 mg tablet (6 mg dose).

http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm296901.pdf

We are planning to conduct bioequivalence study for Ivermectin 3mg tablets for EU. The product administration posology ranges from 1 tablets to 8 tablets depending upon body weight. Link to SmPC of one of the available generic product is given below for ready reference.

http://db.cbg-meb.nl/IB-teksten/h117488_fsuk.pdf

Please suggest which dose to be used in BE study for EU market (1 tablet of 3 mg or 2 tablets of 3 mg or any other dose).

Thanks.

Kind regards

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,638 registered users;
73 visitors (0 registered, 73 guests [including 7 identified bots]).
Forum time: 17:00 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5